Polyclonal Antibody to Macrophage Inflammatory Protein 3 Beta (MIP3b)
Code | Size | Price |
---|
PAA096Hu01-20ul | 20ul | £81.00 |
Quantity:
PAA096Hu01-100ul | 100ul | £149.00 |
Quantity:
PAA096Hu01-200ul | 200ul | £200.00 |
Quantity:
PAA096Hu01-1ml | 1ml | £454.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCL19; CKb11; ELC; MIP3-B; SCYA19; Chemokine C-C-Motif Ligand 19; Beta Chemokine Exodus-3; CK Beta-11; EBI1-Ligand Chemokine; Small Inducible Cytokine Subfamily A19
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Macrophage Inflammatory Protein 3 Beta
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Macrophage Inflammatory Protein 3 Beta (MIP3b) | RPA096Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||